Sickle cell gene therapy makers are considering paying for fertility services in a Medicaid payment model. The world's most expensive treatment for young children offers a near-cure, with drugmakers aiming to make treatments easier to manufacture and reach more patients. The backstory of the expensive drug is shared, highlighting the impact on the developer. A CAR-T treatment, NexCAR19, brings hope for wider availability in low- and middle-income countries.
The CAR-T treatment, called NexCAR19, raises hopes that this transformative class of medicine will become more readily available in low- and middle-income countries https://t.co/74ZxhhLRK2
"I can carry the grief of my daughter’s death more easily now, knowing the world has changed because of her": @Jasonmmast @MeganMolteni recount the fascinating backstory of the world's most expensive drug https://t.co/9711McfAr6 via @statnews
Although CRISPR-based gene therapy for sickle cell disease offers transformative outcomes, drugmakers are striving to develop treatments that are easy to manufacture and can reach much larger numbers of patients https://t.co/8DVOmjFfUi
The world's most expensive treatment offers a near-cure for young children and redemption for its developer, but steep challenges still loom. https://t.co/0KX0zBLAfV
Sickle Cell Gene Therapy Makers Would Pay For Fertility Services In Medicaid Payment Model https://t.co/dJyUb7b1HS #PinkSheet